#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	16010	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2340	832.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1585	1585	C	1039	C,T,G	1036,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26688	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3980	834.5	0	.	n	.	0	T695C	SNP	695	695	T	1198	1198	C	1025	C,T	1024,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26688	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3980	834.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1840	1840	A	1030	A,C	1028,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26688	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3980	834.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2474	2474	C	1021	C	1021	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26688	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3980	834.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2548	2548	A	949	A,C	947,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26688	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3980	834.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	3100	3100	C	1023	C,A	1021,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2336	folP	852	852	100.0	folP.l6.c4.ctg.1	2034	142.9	1	SNP	p	R228S	1	.	.	682	684	AGC	1279	1281	AGC	228;224;227	A;G;C,G	228;224;226,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5184	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3920	164.9	1	SNP	p	S91F	0	.	.	271	273	TCC	808	810	TCC	194;196;195	T;C;C	194;196;195	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5184	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3920	164.9	1	SNP	p	D95N	0	.	.	283	285	GAC	820	822	GAC	207;205;206	G;A;C	207;205;206	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5184	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3920	164.9	1	SNP	p	D95G	0	.	.	283	285	GAC	820	822	GAC	207;205;206	G;A;C	207;205;206	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.Neisseria_meningitidis_H44_76_v1_00513	mtrR.Neisseria_meningitidis_H44_76_v1_00513	1	1	27	2104	mtrR	633	633	99.84	mtrR.l6.c4.ctg.1	1745	150.1	1	SNP	p	G45D	0	.	.	133	135	GGC	712	714	GGC	253;253;256	G;G,A;C	253;252,1;256	mtrR.Neisseria_meningitidis_H44_76_v1_00513:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	218	mtrR_promoter	250	193	95.85	mtrR_promoter.l15.c4.ctg.1	1465	18.5	0	.	n	.	0	A125G	SNP	125	125	A	812	812	G	68	G,C	67,1	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	218	mtrR_promoter	250	193	95.85	mtrR_promoter.l15.c4.ctg.1	1465	18.5	0	.	n	.	0	C147T	SNP	147	147	C	834	834	T	75	T	75	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	218	mtrR_promoter	250	193	95.85	mtrR_promoter.l15.c4.ctg.1	1465	18.5	0	.	n	.	0	T159C	SNP	159	159	T	846	846	C	75	C	75	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	218	mtrR_promoter	250	193	95.85	mtrR_promoter.l15.c4.ctg.1	1465	18.5	0	.	n	.	0	A178.	DEL	178	178	A	864	864	T	76	T	76	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	218	mtrR_promoter	250	193	95.85	mtrR_promoter.l15.c4.ctg.1	1465	18.5	0	.	n	.	0	C189T	SNP	189	189	C	875	875	T	62	T	62	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	218	mtrR_promoter	250	193	95.85	mtrR_promoter.l15.c4.ctg.1	1465	18.5	0	.	n	.	0	A192T	SNP	192	192	A	878	878	T	56	T	56	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	218	mtrR_promoter	250	193	95.85	mtrR_promoter.l15.c4.ctg.1	1465	18.5	0	.	n	.	0	A195C	SNP	195	195	A	881	881	C	56	C	56	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	218	mtrR_promoter	250	193	95.85	mtrR_promoter.l15.c4.ctg.1	1465	18.5	0	.	n	.	0	G221A	SNP	221	221	G	907	907	A	43	A	43	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5274	parC	2304	2304	100.0	parC.l15.c17.ctg.1	3401	193.0	1	SNP	p	D86N	0	.	.	256	258	GAC	798	800	GAC	229;228;228	G;A;C	229;228;228	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5274	parC	2304	2304	100.0	parC.l15.c17.ctg.1	3401	193.0	1	SNP	p	S87I	0	.	.	259	261	AGT	801	803	AGT	225;229;227	A;G;T	225;229;227	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5274	parC	2304	2304	100.0	parC.l15.c17.ctg.1	3401	193.0	1	SNP	p	S87R	0	.	.	259	261	AGT	801	803	AGT	225;229;227	A;G;T	225;229;227	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5274	parC	2304	2304	100.0	parC.l15.c17.ctg.1	3401	193.0	1	SNP	p	S87W	0	.	.	259	261	AGT	801	803	AGT	225;229;227	A;G;T	225;229;227	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5274	parC	2304	2304	100.0	parC.l15.c17.ctg.1	3401	193.0	1	SNP	p	S88P	0	.	.	262	264	TCC	804	806	TCC	224;226;226	T,C;C;C	223,1;226;226	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4544	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3196	177.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1784	1786	GGC	251;248;246	G;G;C,T	251;248;245,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4496	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2860	195.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1490	1492	GCA	277;274;278	G;C,G;A	277;273,1;278	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4496	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2860	195.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1493	1495	ATC	278;275;277	A;T,G;C,T,G,A	278;274,1;274,1,1,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4496	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2860	195.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1505	1507	GTG	279;282;284	G,C;T,G;G	278,1;280,2;284	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4496	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2860	195.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1505	1507	GTG	279;282;284	G,C;T,G;G	278,1;280,2;284	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4496	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2860	195.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2009	2011	ACC	270;273;271	A,C,T,G;C;C	266,2,1,1;273;271	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4496	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2860	195.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2063	2065	GCG	265;265;264	G;C,G;G	265;264,1;264	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4496	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2860	195.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2063	2065	GCG	265;265;264	G;C,G;G	265;264,1;264	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4496	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2860	195.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2186	2188	GGC	251;254;251	G;G,T;C	251;253,1;251	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4496	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2860	195.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2195	2197	GGC	249;248;252	G,A;G;C	248,1;248;252	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4496	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2860	195.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2213	2215	CCG	246;251;248	C,G;C;G,C	243,2;250;246,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5852	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3489	208.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2468	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2271	135.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	811	811	C	206	C	206	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	27	3288	porB1b	1047	1047	100.0	porB1b.l6.c4.ctg.1	2159	189.6	1	SNP	p	G120K	0	.	.	358	360	GGC	854	856	GGC	269;268;268	G;G,T;C	269;267,1;268	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	27	3288	porB1b	1047	1047	100.0	porB1b.l6.c4.ctg.1	2159	189.6	1	SNP	p	A121D	1	.	.	361	363	GAC	857	859	GAC	269;268;267	G;A;C,A	269;268;266,1	porB1b.WHO_P_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	27	3288	porB1b	1047	1047	100.0	porB1b.l6.c4.ctg.1	2159	189.6	1	SNP	p	D121N	0	.	.	361	363	GAC	857	859	GAC	269;268;267	G;A;C,A	269;268;266,1	porB1b.WHO_P_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10594	rpoB	4179	4179	99.98	rpoB.l15.c30.ctg.1	5301	249.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1566	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1435	135.5	1	SNP	p	V57M	1	.	.	169	171	ATG	727	729	ATG	283;286;287	A;T;G,T	283;286;286,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
